Brazil's Interfarma estimates maximum adjustment of medicines prices at 4.76%

11 March 2017

Based on inflation in February, the Brazilian pharma industry trade group Interfarma estimates at 4.76% the maximum index of adjustment for medications.

Two other lower tracks are also forecast and were estimated at 3.06% and 1.36%. The level of adjustments is once again lower than inflation as it has been almost every year since 2005, the association noted in a website posting on Friday.

“The adjustment is not totally applied in practice because market competition results in discounts reflected in pharmacy sales. There are also obligatory government discounts, as well as negotiated rebates,” highlights Antônio Britto, executive president of Interfarma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK